Search alternatives:
decrease » decreased (Expand Search), increase (Expand Search)
Showing 61 - 80 results of 645 for search '(( 50 a decrease ) OR ((((( 5 ppm decrease ) OR ( 5 point decrease ))) OR ( 10 i decrease ))))', query time: 0.19s Refine Results
  1. 61

    Soluble Neuropilin-1 Response to Hypoglycemia in Type 2 Diabetes: Increased Risk or Protection in SARS-CoV-2 Infection? by Abu Saleh Md Moin (6189512)

    Published 2021
    “…SEMA3A was not different at baseline; at hypoglycemia, SEMA3A decreased in controls only. Post-hypoglycemia, SEMA3A levels were higher in T2D versus controls. sNRP1 did not correlate with ACE2, REN or AGT. …”
  2. 62

    Antibody‐based methods for the measurement of α‐synuclein concentration in human cerebrospinal fluid – method comparison and round robin study by Brit Mollenhauer (482499)

    Published 2018
    “…</p><h2>Other Information</h2><p dir="ltr">Published in: Journal of Neurochemistry<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1111/jnc.14569" target="_blank">https://dx.doi.org/10.1111/jnc.14569</a></p><p dir="ltr"><br></p>…”
  3. 63
  4. 64

    Studies of Glyoxalase 1-Linked Multidrug Resistance Reveal Glycolysis-Derived Reactive Metabolite, Methylglyoxal, Is a Common Contributor in Cancer Chemotherapy Targeting the Splic... by Muhanad Alhujaily (11630107)

    Published 2021
    “…Spliceosomal gene expression correlated positively with Glo1 in human tumor cell lines and tumors. In clinical chemotherapy of breast cancer, increased expression of Glo1 was associated with decreased patient survival, with hazard ratio (HR) = 1.82 (logrank p < 0.001, n = 683) where upper quartile survival of patients was decreased by 64% with high Glo1 expression.…”
  5. 65
  6. 66

    The effects of long-term testosterone treatment on endocrine parameters in hypogonadal men: 12-year data from a prospective controlled registry study by Aksam Yassin (14779204)

    Published 2022
    “…This was accompanied by an increase in estradiol levels by 14.9 pmol/L (<i>p</i> < 0.0001), and decreases in progesterone (0.2 ng/mL, <i>p</i> < 0.0001), LH (10.4 U/L, <i>p</i> < 0.0001) and FSH (8.4 U/L, <i>p</i> < 0.0001) were demonstrated at 12-years. …”
  7. 67

    Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1 by Natalie C Galles (9715361)

    Published 2021
    “…Third-dose polio vaccine (Pol3) coverage also increased, from 42·6% (41·4–44·1) in 1980 to 79·8% (78·4–81·1) in 2019, and global coverage of newer vaccines increased rapidly between 2000 and 2019. …”
  8. 68

    The molecular mechanisms of apoptosis accompanied with the epigenetic regulation of the NY-ESO-1 antigen in non-small lung cancer cells treated with decitabine (5-aza-CdR) by Varghese P. Inchakalody (14557382)

    Published 2023
    “…These results reiterate the decisive role of 5-Aza-CdR in lung cancer treatment since it induces the epigenetic regulation of NY-ESO-1 antigen, inhibits cell proliferation, increases apoptosis, and decreases invasiveness.…”
  9. 69

    The effect of Ramadan focused education on patients with type 2 diabetes: A systematic review and meta-analysis by Hoda Gad (6470522)

    Published 2020
    “…Quality assessment was done using the ROBINS-I and Cochrane tools for risk of bias and analyses were performed using RevMan version 5.1.…”
  10. 70

    Exploring Beyond Numeric Weight Loss: The Metabolic Effects of Semaglutide. by Sara, Sokary

    Published 2025
    “…Also, it enhanced glycemic control, as evidenced by significant reductions in hemoglobin A1C (HbA1c) with the 0.5 mg and 1.0 mg doses. From a baseline range of 8.1–8.7%, 0.5mg dose lowered HbA1c by 1.2–1.5%, while the 1.0 mg dose reduced it by 1.4–1.8%. …”
    Get full text
    Get full text
    Get full text
    article
  11. 71

    Ablation of LAT2 Transporter Causes Intramuscular Glutamine Accumulation and Inhibition of Fasting‐Induced Proteolysis by Meritxell Espino‐Guarch (22565774)

    Published 2025
    “…Ex vivo incubation of LAT2KO muscle with rapamycin recovered proteolysis function, demonstrating a mTORC1‐dependent pathway. Decreased proteolysis in LAT2KO animals was associated with increased mTORC1 translocation to the lysosome (mTORC1‐Lamp1 colocalization in fasted LAT2KO muscles was 1.23‐fold, <i>p</i> < 0.0001). …”
  12. 72

    The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polyc... by Thozhukat Sathyapalan (704787)

    Published 2019
    “…</p><h3>Conclusions</h3><p dir="ltr">This post-hoc analysis revealed that 12 weeks of atorvastatin treatment significantly decreased the markers of adipose tissue dysfunction and inflammation, namely ASP, IL-6 and MCP-1 in obese women with PCOS. …”
  13. 73

    Comparative Genomic Mapping Implicates LRRK2 for Intellectual Disability and Autism at 12q12, and HDHD1, as Well as PNPLA4, for X-Linked Intellectual Disability at Xp22.31 by Jonathan D. J. Labonne (18090841)

    Published 2020
    “…<p dir="ltr">We report a genomic and phenotypic delineation for two chromosome regions with candidate genes for syndromic intellectual disability at 12q12 and Xp22.31, segregating independently in one family with four affected members. Fine mapping of three affected members, along with six unreported small informative CNVs, narrowed down the candidate chromosomal interval to one gene LRRK2 at 12q12. …”
  14. 74

    Clinical and biochemical determinants of length of stay, readmission and recurrence in patients admitted with diabetic ketoacidosis by Fateen Ata (12217764)

    Published 2023
    “…The median LOS was 2.6 days (IQR 1.1–4.8), and the median DKA resolution time was 18 h (10.5–29). …”
  15. 75

    Tolfenamic Acid Derivatives: A New Class of Transcriptional Modulators with Potential Therapeutic Applications for Alzheimer’s Disease and Related Disorders by Jaunetta Hill (18255631)

    Published 2023
    “…More importantly, the proteome of treated cells displayed ~75% of the downregulated products as SP1 targets. Specific levels of SP1-driven genes and AD biomarkers such as amyloid precursor protein (APP) and Tau proteins were also decreased as part of this targeted systemic response. …”
  16. 76

    Correlating the rheological and magneto-optical properties of cobalt substituted magnetite ferrofluids (Co<sub>x</sub>Fe<sub>1−x</sub>Fe<sub>2</sub>O<sub>4</sub>) with theoretical... by Blessy Babukutty (17871482)

    Published 2023
    “…</p><h2>Other Information</h2><p dir="ltr">Published in: Results in Materials<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.rinma.2023.100382" target="_blank">https://dx.doi.org/10.1016/j.rinma.2023.100382</a></p>…”
  17. 77

    The Effect of Soy Isoflavones on Steroid Metabolism by Amanda C. Swart (18153814)

    Published 2019
    “…In addition, 3βHSD2 was inhibited perhaps accounting for decreased A4 levels observed in females. The decreased DHEAS and A4 levels together with the inhibition of the 17,20 lyase activity of CYP17A1, may impact production of androgens in clinical conditions associated with androgen excess.…”
  18. 78

    The promise of tirzepatide: A narrative review of metabolic benefits by Sara Sokary (17337724)

    Published 2025
    “…</p><h2>Other Information</h2> <p> Published in: Primary Care Diabetes<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.pcd.2025.03.008" target="_blank">https://dx.doi.org/10.1016/j.pcd.2025.03.008</a></p>…”
  19. 79
  20. 80

    Exploring beyond numeric weight loss: The metabolic effects of semaglutide by Sara Sokary (17337724)

    Published 2025
    “…Also, it enhanced glycemic control, as evidenced by significant reductions in hemoglobin A1C (HbA1c) with the 0.5 mg and 1.0 mg doses. From a baseline range of 8.1–8.7 %, 0.5 mg dose lowered HbA1c by 1.2–1.5 %, while the 1.0 mg dose reduced it by 1.4–1.8 %. …”